Pancreatic Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Pancreatic Cancer – Pipeline Review, H2 2016’, provides an overview of the Pancreatic Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pancreatic Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Pancreatic Cancer

The report reviews pipeline therapeutics for Pancreatic Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Pancreatic Cancer therapeutics and enlists all their major and minor projects

The report assesses Pancreatic Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Pancreatic Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pancreatic Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pancreatic Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3M Drug Delivery Systems

4SC AG

AB Science SA

AbbVie Inc

AbGenomics International Inc

Ability Pharmaceuticals SL

Acetylon Pharmaceuticals Inc

Adamed Sp z oo

Adamis Pharmaceuticals Corp

Aduro BioTech Inc

Advantagene Inc

Advaxis Inc

Agenus Inc

AGV Discovery SAS

AIMM Therapeutics BV

Alchemia Ltd

Alissa Pharma

Allinky Biopharma

Almac Discovery Ltd

Altor BioScience Corp

Ambrx Inc

amcure GmbH

American Gene Technologies International Inc

Amgen Inc

Anavex Life Sciences Corp

Andarix Pharmaceuticals Inc

ANP Technologies Inc

AntiCancer Inc

APEIRON Biologics AG

Aphios Corp

APIM Therapeutics AS

Apogenix GmbH

Aposense Ltd

ARMO Biosciences Inc

ArQule Inc

Array BioPharma Inc

Astellas Pharma Inc

AstraZeneca Plc

ATLAB Pharma SAS

Aurigene Discovery Technologies Ltd

AVEO Pharmaceuticals Inc

Axcentua Pharmaceuticals AB

Azaya Therapeutics Inc

Basilea Pharmaceutica Ltd

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Bellicum Pharmaceuticals Inc

Berg LLC

BerGenBio AS

Betta Pharmaceuticals Co Ltd

Bexion Pharmaceuticals LLC

BeyondSpring Pharmaceuticals Inc

Bio-Path Holdings Inc

BioLineRx Ltd

Biomar Microbial Technologies

Biomunex Pharmaceuticals

Bioncotech Therapeutics SL

Bionomics Ltd

BioNTech AG

BiOrion Technologies BV

Biotest AG

Biouniversa srl

BLR Bio LLC

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Cadila Pharmaceuticals Ltd

Calithera Biosciences Inc

Cantargia AB

Cascadian Therapeutics Inc

Cavion LLC

Celgene Corp

Cellceutix Corp

Cellular Biomedicine Group Inc

Celprogen Inc

Celyad SA

Centrose LLC

Ceronco Biosciences

ChemoCentryx Inc

Chiome Bioscience Inc

Chugai Pharmaceutical Co Ltd

Clovis Oncology Inc

COARE Biotechnology Inc

Concordia International Corp

Confluence Life Sciences Inc

Cornerstone Pharmaceuticals Inc

Critical Outcome Technologies Inc

CrystalGenomics Inc

CTI BioPharma Corp

Cyclacel Pharmaceuticals Inc

CytomX Therapeutics Inc

CytRx Corp

CyTuVax BV

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Company Ltd

DEKK-TEC Inc

Diffusion Pharmaceuticals Inc

Eisai Co Ltd

Eleison Pharmaceuticals LLC

Eli Lilly and Company

Endor Nanotechnologies SL

Ensemble Therapeutics Corp

Ensol Biosciences Inc

Erytech Pharma SA

Esperance Pharmaceuticals Inc

Etubics Corp

Exelixis Inc

F. Hoffmann-La Roche Ltd

FibroGen Inc

Five Prime Therapeutics Inc

Fountain Biopharma Inc

Fujifilm Corp

Fusion Antibodies Ltd

Galena Biopharma Inc

GamaMabs Pharma SA

Ganymed Pharmaceuticals AG

Geistlich Pharma AG

Genelux Corp

Genentech Inc

Genisphere Inc

Genmab A/S

Gilead Sciences Inc

GlaxoSmithKline Plc

Globeimmune Inc

GlycoMimetics Inc

Golden Biotechnology Corp

GW Pharmaceuticals Plc

Halozyme Therapeutics Inc

HEC Pharm Co Ltd

Helix BioPharma Corp

Horizon Pharma Plc

iCeutica Inc

Igenica Biotherapeutics Inc

Ignyta Inc

Immodulon Therapeutics Ltd

Immune Pharmaceuticals Inc

Immune System Key Ltd

Immune Therapeutics Inc

Immunomedics Inc

Immunotope Inc

Immunovo BV

Immupharma Plc

Incuron LLC

Incyte Corp

Inflection Biosciences Ltd

Innopharmax Inc

Inovio Pharmaceuticals Inc

InteRNA Technologies BV

Intica Biomedical Inc

Inventiva

InvivoGen Therapeutics

Io Therapeutics Inc

ISU ABXIS Co Ltd

Jasco Pharmaceuticals LLC

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Juno Therapeutics Inc

Kadmon Corp LLC

Kancera AB

Karcinolys SAS

Karyopharm Therapeutics Inc

Keystone Nano Inc

Komipharm International Co Ltd

Kura Oncology Inc

Kyowa Hakko Kirin Co Ltd

Lead Discovery Center GmbH

Lion Biotechnologies Inc

Lymphocyte Activation Technologies SA

MabVax Therapeutics Holdings Inc

MacroGenics Inc

Mateon Therapeutics Inc

MaxiVAX SA

Meabco A/S

Mebiopharm Co Ltd

MediaPharma srl

Medicenna Therapeutics Inc

MedImmune LLC

Medisyn Technologies Inc

Medivation Inc

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Merus NV

Moleculin Biotech Inc

MolMed SpA

Monopar Therapeutics LLC

Morphotek Inc

Multimmune GmbH

NanoCarrier Co Ltd

NantKwest Inc

Nascent Biotech Inc

Natco Pharma Ltd

NatureWise Biotech & Medicals Corp

Nerviano Medical Sciences Srl

NewLink Genetics Corp

NormOxys Inc

Northwest Biotherapeutics Inc

Novartis AG

Noxxon Pharma AG

NuCana BioMed Ltd

Omeros Corp

Omnitura Therapeutics Inc

Oncodesign SA

Oncology Research International Ltd

Oncolytics Biotech Inc

Oncomatryx Biopharma SL

OncoMed Pharmaceuticals Inc

OncoTherapy Science Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Onxeo SA

Opsona Therapeutics Ltd

Optimum Therapeutics LLC

Orega Biotech SAS

Oribase Pharma

Oryx GmbH & Co KG

Oscotec Inc

Patrys Ltd

Pfizer Inc

Pharma Two B Ltd

PharmAbcine Inc

Pharmacyclics Inc

PharmaCyte Biotech Inc

Pharmedartis GmbH

Phoenix Biotechnology Inc

Pique Therapeutics

Plexxikon Inc

Polaris Pharmaceuticals Inc

Precision Biologics Inc

Prima BioMed Ltd

ProNAi Therapeutics Inc

Propanc Health Group Corp

Provectus Biopharmaceuticals Inc

Quest PharmaTech Inc

Quimatryx SL

RedHill Biopharma Ltd

Redx Pharma Plc

RESprotect GmbH

Rexahn Pharmaceuticals Inc

Rhizen Pharmaceuticals SA

Rigontec GmbH

Samumed LLC

Sanofi

Sapience Therapeutics Inc

Sareum Holdings Plc

SATT North SAS

Savoy Pharmaceuticals Inc

SignPath Pharma Inc

Silence Therapeutics Plc

Sillajen Biotherapeutics

Soluventis GmbH

Soricimed Biopharma Inc

Spotlight Innovation Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 14

Pancreatic Cancer Overview 15

Therapeutics Development 16

Pancreatic Cancer - Therapeutics under Development by Companies 18

Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes 45

Pancreatic Cancer - Pipeline Products Glance 49

Pancreatic Cancer - Products under Development by Companies 53

Pancreatic Cancer - Products under Investigation by Universities/Institutes 88

Pancreatic Cancer - Companies Involved in Therapeutics Development 93

Pancreatic Cancer - Therapeutics Assessment 397

Drug Profiles 478

Pancreatic Cancer - Dormant Projects 1889

Pancreatic Cancer - Discontinued Products 1922

Pancreatic Cancer - Product Development Milestones 1929

Appendix 1942

List of Tables

List of Tables

Number of Products under Development for Pancreatic Cancer, H2 2016 79

Number of Products under Development for Pancreatic Cancer – Comparative Analysis, H2 2016 80

Number of Products under Development by Companies, H2 2016 82

Number of Products under Development by Companies, H2 2016 (Contd..1) 83

Number of Products under Development by Companies, H2 2016 (Contd..2) 84

Number of Products under Development by Companies, H2 2016 (Contd..3) 85

Number of Products under Development by Companies, H2 2016 (Contd..4) 86

Number of Products under Development by Companies, H2 2016 (Contd..5) 87

Number of Products under Development by Companies, H2 2016 (Contd..6) 88

Number of Products under Development by Companies, H2 2016 (Contd..7) 89

Number of Products under Development by Companies, H2 2016 (Contd..8) 90

Number of Products under Development by Companies, H2 2016 (Contd..9) 91

Number of Products under Development by Companies, H2 2016 (Contd..10) 92

Number of Products under Development by Companies, H2 2016 (Contd..11) 93

Number of Products under Development by Companies, H2 2016 (Contd..12) 94

Number of Products under Development by Companies, H2 2016 (Contd..13) 95

Number of Products under Development by Companies, H2 2016 (Contd..14) 96

Number of Products under Development by Companies, H2 2016 (Contd..15) 97

Number of Products under Development by Companies, H2 2016 (Contd..16) 98

Number of Products under Development by Companies, H2 2016 (Contd..17) 99

Number of Products under Development by Companies, H2 2016 (Contd..18) 100

Number of Products under Development by Companies, H2 2016 (Contd..19) 101

Number of Products under Development by Companies, H2 2016 (Contd..20) 102

Number of Products under Development by Companies, H2 2016 (Contd..21) 103

Number of Products under Development by Companies, H2 2016 (Contd..22) 104

Number of Products under Development by Companies, H2 2016 (Contd..23) 105

Number of Products under Development by Companies, H2 2016 (Contd..24) 106

Number of Products under Development by Companies, H2 2016 (Contd..25) 107

Number of Products under Investigation by Universities/Institutes, H2 2016 108

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 109

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 110

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 111

Comparative Analysis by Late Stage Development, H2 2016 112

Comparative Analysis by Clinical Stage Development, H2 2016 113

Comparative Analysis by Early Stage Development, H2 2016 114

Comparative Analysis by Unknown Stage Development, H2 2016 115

Products under Development by Companies, H2 2016 116

Products under Development by Companies, H2 2016 (Contd..1) 117

Products under Development by Companies, H2 2016 (Contd..2) 118

Products under Development by Companies, H2 2016 (Contd..3) 119

Products under Development by Companies, H2 2016 (Contd..4) 120

Products under Development by Companies, H2 2016 (Contd..5) 121

Products under Development by Companies, H2 2016 (Contd..6) 122

Products under Development by Companies, H2 2016 (Contd..7) 123

Products under Development by Companies, H2 2016 (Contd..8) 124

Products under Development by Companies, H2 2016 (Contd..9) 125

Products under Development by Companies, H2 2016 (Contd..10) 126

Products under Development by Companies, H2 2016 (Contd..11) 127

Products under Development by Companies, H2 2016 (Contd..12) 128

Products under Development by Companies, H2 2016 (Contd..13) 129

Products under Development by Companies, H2 2016 (Contd..14) 130

Products under Development by Companies, H2 2016 (Contd..15) 131

Products under Development by Companies, H2 2016 (Contd..16) 132

Products under Development by Companies, H2 2016 (Contd..17) 133

Products under Development by Companies, H2 2016 (Contd..18) 134

Products under Development by Companies, H2 2016 (Contd..19) 135

Products under Development by Companies, H2 2016 (Contd..20) 136

Products under Development by Companies, H2 2016 (Contd..21) 137

Products under Development by Companies, H2 2016 (Contd..22) 138

Products under Development by Companies, H2 2016 (Contd..23) 139

Products under Development by Companies, H2 2016 (Contd..24) 140

Products under Development by Companies, H2 2016 (Contd..25) 141

Products under Development by Companies, H2 2016 (Contd..26) 142

Products under Development by Companies, H2 2016 (Contd..27) 143

Products under Development by Companies, H2 2016 (Contd..28) 144

Products under Development by Companies, H2 2016 (Contd..29) 145

Products under Development by Companies, H2 2016 (Contd..30) 146

Products under Development by Companies, H2 2016 (Contd..31) 147

Products under Development by Companies, H2 2016 (Contd..32) 148

Products under Development by Companies, H2 2016 (Contd..33) 149

Products under Development by Companies, H2 2016 (Contd..34) 150

Products under Investigation by Universities/Institutes, H2 2016 151

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 152

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 153

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 154

Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 155

Pancreatic Cancer – Pipeline by 3M Drug Delivery Systems, H2 2016 156

Pancreatic Cancer – Pipeline by 4SC AG, H2 2016 157

Pancreatic Cancer – Pipeline by AB Science SA, H2 2016 158

Pancreatic Cancer – Pipeline by AbbVie Inc, H2 2016 159

Pancreatic Cancer – Pipeline by AbGenomics International Inc, H2 2016 160

Pancreatic Cancer – Pipeline by Ability Pharmaceuticals SL, H2 2016 161

Pancreatic Cancer – Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 162

Pancreatic Cancer – Pipeline by Adamed Sp z oo, H2 2016 163

Pancreatic Cancer – Pipeline by Adamis Pharmaceuticals Corp, H2 2016 164

Pancreatic Cancer – Pipeline by Aduro BioTech Inc, H2 2016 165

Pancreatic Cancer – Pipeline by Advantagene Inc, H2 2016 166

Pancreatic Cancer – Pipeline by Advaxis Inc, H2 2016 167

Pancreatic Cancer – Pipeline by Agenus Inc, H2 2016 168

Pancreatic Cancer – Pipeline by AGV Discovery SAS, H2 2016 169

Pancreatic Cancer – Pipeline by AIMM Therapeutics BV, H2 2016 170

Pancreatic Cancer – Pipeline by Alchemia Ltd, H2 2016 171

Pancreatic Cancer – Pipeline by Alissa Pharma, H2 2016 172

Pancreatic Cancer – Pipeline by Allinky Biopharma, H2 2016 173

Pancreatic Cancer – Pipeline by Almac Discovery Ltd, H2 2016 174

Pancreatic Cancer – Pipeline by Altor BioScience Corp, H2 2016 175

Pancreatic Cancer – Pipeline by Ambrx Inc, H2 2016 176

Pancreatic Cancer – Pipeline by amcure GmbH, H2 2016 177

Pancreatic Cancer – Pipeline by American Gene Technologies International Inc, H2 2016 178

Pancreatic Cancer – Pipeline by Amgen Inc, H2 2016 179

Pancreatic Cancer – Pipeline by Anavex Life Sciences Corp, H2 2016 180

Pancreatic Cancer – Pipeline by Andarix Pharmaceuticals Inc, H2 2016 181

Pancreatic Cancer – Pipeline by ANP Technologies Inc, H2 2016 182

Pancreatic Cancer – Pipeline by AntiCancer Inc, H2 2016 183

Pancreatic Cancer – Pipeline by APEIRON Biologics AG, H2 2016 184

Pancreatic Cancer – Pipeline by Aphios Corp, H2 2016 185

Pancreatic Cancer – Pipeline by APIM Therapeutics AS, H2 2016 186

Pancreatic Cancer – Pipeline by Apogenix GmbH, H2 2016 187

Pancreatic Cancer – Pipeline by Aposense Ltd, H2 2016 188

Pancreatic Cancer – Pipeline by ARMO Biosciences Inc, H2 2016 189

Pancreatic Cancer – Pipeline by ArQule Inc, H2 2016 190

Pancreatic Cancer – Pipeline by Array BioPharma Inc, H2 2016 191

Pancreatic Cancer – Pipeline by Astellas Pharma Inc, H2 2016 192

Pancreatic Cancer – Pipeline by AstraZeneca Plc, H2 2016 193

Pancreatic Cancer – Pipeline by ATLAB Pharma SAS, H2 2016 194

Pancreatic Cancer – Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 195

Pancreatic Cancer – Pipeline by AVEO Pharmaceuticals Inc, H2 2016 196

Pancreatic Cancer – Pipeline by Axcentua Pharmaceuticals AB, H2 2016 197

Pancreatic Cancer – Pipeline by Azaya Therapeutics Inc, H2 2016 198

Pancreatic Cancer – Pipeline by Basilea Pharmaceutica Ltd, H2 2016 199

Pancreatic Cancer – Pipeline by Bavarian Nordic A/S, H2 2016 200

Pancreatic Cancer – Pipeline by Bayer AG, H2 2016 201

Pancreatic Cancer – Pipeline by BeiGene Ltd, H2 2016 202

Pancreatic Cancer – Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 203

Pancreatic Cancer – Pipeline by Berg LLC, H2 2016 204

Pancreatic Cancer – Pipeline by BerGenBio AS, H2 2016 205

Pancreatic Cancer – Pipeline by Betta Pharmaceuticals Co Ltd, H2 2016 206

Pancreatic Cancer – Pipeline by Bexion Pharmaceuticals LLC, H2 2016 207

Pancreatic Cancer – Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016 208

Pancreatic Cancer – Pipeline by Bio-Path Holdings Inc, H2 2016 209

Pancreatic Cancer – Pipeline by BioLineRx Ltd, H2 2016 210

Pancreatic Cancer – Pipeline by Biomar Microbial Technologies, H2 2016 211

Pancreatic Cancer – Pipeline by Biomunex Pharmaceuticals, H2 2016 212

Pancreatic Cancer – Pipeline by Bioncotech Therapeutics SL, H2 2016 213

Pancreatic Cancer – Pipeline by Bionomics Ltd, H2 2016 214

Pancreatic Cancer – Pipeline by BioNTech AG, H2 2016 215

Pancreatic Cancer – Pipeline by BiOrion Technologies BV, H2 2016 216

Pancreatic Cancer – Pipeline by Biotest AG, H2 2016 217

Pancreatic Cancer – Pipeline by Biouniversa srl, H2 2016 218

Pancreatic Cancer – Pipeline by BLR Bio LLC, H2 2016 219

Pancreatic Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2016 220

Pancreatic Cancer – Pipeline by Boston Biomedical Inc, H2 2016 221

Pancreatic Cancer – Pipeline by Bristol-Myers Squibb Company, H2 2016 222

Pancreatic Cancer – Pipeline by Cadila Pharmaceuticals Ltd, H2 2016 223

Pancreatic Cancer – Pipeline by Calithera Biosciences Inc, H2 2016 224

Pancreatic Cancer – Pipeline by Cantargia AB, H2 2016 225

Pancreatic Cancer – Pipeline by Cascadian Therapeutics Inc, H2 2016 226

Pancreatic Cancer – Pipeline by Cavion LLC, H2 2016 227

Pancreatic Cancer – Pipeline by Celgene Corp, H2 2016 228

Pancreatic Cancer – Pipeline by Cellceutix Corp, H2 2016 229

Pancreatic Cancer – Pipeline by Cellular Biomedicine Group Inc, H2 2016 230

Pancreatic Cancer – Pipeline by Celprogen Inc, H2 2016 231

Pancreatic Cancer – Pipeline by Celyad SA, H2 2016 232

Pancreatic Cancer – Pipeline by Centrose LLC, H2 2016 233

Pancreatic Cancer – Pipeline by Ceronco Biosciences, H2 2016 234

Pancreatic Cancer – Pipeline by ChemoCentryx Inc, H2 2016 235

Pancreatic Cancer – Pipeline by Chiome Bioscience Inc, H2 2016 236

Pancreatic Cancer – Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 237

Pancreatic Cancer – Pipeline by Clovis Oncology Inc, H2 2016 238

Pancreatic Cancer – Pipeline by COARE Biotechnology Inc, H2 2016 239

Pancreatic Cancer – Pipeline by Concordia International Corp, H2 2016 240

Pancreatic Cancer – Pipeline by Confluence Life Sciences Inc, H2 2016 241

Pancreatic Cancer – Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 242

Pancreatic Cancer – Pipeline by Critical Outcome Technologies Inc, H2 2016 243

Pancreatic Cancer – Pipeline by CrystalGenomics Inc, H2 2016 244

Pancreatic Cancer – Pipeline by CTI BioPharma Corp, H2 2016 245

Pancreatic Cancer – Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 246

Pancreatic Cancer – Pipeline by CytomX Therapeutics Inc, H2 2016 247

List of Figures

List of Figures

Number of Products under Development for Pancreatic Cancer, H2 2016 79

Number of Products under Development for Pancreatic Cancer – Comparative Analysis, H2 2016 80

Number of Products under Development by Companies, H2 2016 81

Number of Products under Investigation by Universities/Institutes, H2 2016 108

Comparative Analysis by Late Stage Development, H2 2016 112

Comparative Analysis by Clinical Stage Development, H2 2016 113

Comparative Analysis by Early Stage Products, H2 2016 114

Assessment by Monotherapy Products, H2 2016 460

Assessment by Combination Products, H2 2016 461

Number of Products by Top 10 Targets, H2 2016 462

Number of Products by Stage and Top 10 Targets, H2 2016 462

Number of Products by Top 10 Mechanism of Actions, H2 2016 504

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 504

Number of Products by Top 10 Routes of Administration, H2 2016 537

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 537

Number of Products by Top 10 Molecule Types, H2 2016 539

Number of Products by Stage and Top 10 Molecule Types, H2 2016 539

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports